On August 17, CSPC PHARMA rose 3.22% in regular trading, trading at HKD 8.965 per share, with turnover of HKD 371 million.

On the news front, Hong Kong-listed innovative pharmaceutical stocks collectively strengthened during the session, with HUTCHMED up over 7% and WuXi Biologics up over 5%, providing broad sector tailwinds for CSPC PHARMA. Additionally, the company recently confirmed receipt of a USD 30 million upfront payment from AstraZeneca on August 12 under their siRNA drug collaboration agreement signed in July, and a separate USD 10 million milestone payment on August 5 under a small-molecule research collaboration dating from June 2025. The accelerating pace of international partnership monetization has bolstered investor sentiment.

Within the Pharmaceuticals sector, HENGRUI PHARMA up 2.75%, HUTCHMED up 5.89%, ASYMCHEM up 6.91%, SBP GROUP up 1.36%, HANSOH PHARMA flat.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)